CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
October 05, 2021 16:05 ET
|
CRISPR Therapeutics AG
-Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
October 01, 2021 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
September 28, 2021 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
July 29, 2021 16:30 ET
|
CRISPR Therapeutics AG
- More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Received Orphan Drug Designation...
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
June 15, 2021 07:15 ET
|
CRISPR Therapeutics AG
- Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. and...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
May 25, 2021 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
May 12, 2021 11:00 ET
|
CRISPR Therapeutics AG; Vertex Pharmaceuticals Incorporated
CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two...
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
May 06, 2021 16:01 ET
|
CRISPR Therapeutics AG
-Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities- -Companies to co-develop...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
April 29, 2021 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...